静脉瓣膜PROX1/FOXC2抗血栓通路缺陷驱动创伤与危重症诱导的高凝状态
该研究在小鼠多重伤模型(肝挤压伤、单侧下肢挤压伤及假性骨折、15%总血容量失血)中发现,伤后静脉在凝血酶暴露下凝块覆盖面积增加(45% vs 27%,p=0.0002),提示高凝状态;瓣膜特异性敲除FOXC2(FoxC2del)联合多重伤可致50%动物出现自发性微血栓(χ²检验 p=0.017)。在危重症器官捐献者静脉标本中,免疫荧光显示FOXC2和PROX1表达降低,提示保护性瓣膜表型丢失。作者认为多重伤可诱导类似FOXC2敲除的瓣膜高凝表型,危重症人标本存在振荡剪切应力诱导基因表达丢失,可能与DVT保护性瓣膜表型丧失相关。
要点
- 小鼠多重伤后凝血酶暴露下静脉凝块覆盖面积显著高于未伤组(45% vs 27%,p=0.0002),提示创伤后高凝状态。
- 未操纵的FoxC2敲除小鼠较野生型在静脉瓣膜处凝血增加;多重伤后野生型小鼠凝血增加(p=0.0033),与瓣膜敲除FoxC2表型相当。
- 多重伤联合FoxC2敲除导致50%动物出现自发性微血栓,单独多重伤或单独FoxC2缺陷均未观察到此表型(χ²检验 p=0.017)。
- 危重症器官捐献者静脉免疫荧光显示FOXC2和PROX1表达降低,提示保护性瓣膜表型丢失。
- 该模型无需直接血管损伤或结扎即可研究创伤后自发性DVT和高凝状态。
适用人群与场景
- C57/Bl6小鼠接受改良多重伤模型:肝挤压伤、单侧下肢挤压伤及假性骨折、15%总血容量失血。
- 人类静脉标本来自择期心脏手术多余组织及器官捐献后获取的组织。
处置流程与药物剂量
- 小鼠伤后2、6、24、48小时用酶联免疫吸附法检测血清d-二聚体。
- 凝血酶凝血实验:暴露腿部静脉后,眶后注射100 μL 1 mM罗丹明(6 g),随后静脉表面应用450 μg/mL凝血酶,通过活体免疫荧光显微镜实时观察凝块形成,分析可见小鼠隐静脉和股总静脉的凝块覆盖面积百分比。
- 通过他莫昔芬处理PROX1 Ert2Cre FOXC2 fl/fl小鼠诱导静脉瓣膜特异性FOXC2敲除。
- 伤后24小时通过凝血酶实验检查瓣膜表型,分析隐静脉、胫静脉和股浅静脉交汇处瓣膜附近凝块形成及凝血酶暴露前静脉内自发性微血栓。
- 人静脉切片石蜡包埋后免疫荧光检测PROX1、FOXC2、血栓调节蛋白、内皮蛋白C受体和血管性血友病因子。
研究设计与关键结果
- 研究类型:动物实验(小鼠多重伤模型)及人静脉标本免疫荧光分析。
- 小鼠多重伤后d-二聚体酶联免疫吸附法显示纤维蛋白降解产物,与损伤相关凝块形成、纤溶和/或微血栓形成一致。
- 凝血酶凝血实验显示多重伤动物较未伤动物静脉凝块覆盖面积百分比更高(45% vs 27%,p=0.0002),与创伤后高凝状态表型一致。
- 未操纵的FoxC2敲除小鼠较未操纵野生型动物静脉瓣膜处凝血增加。
- 多重伤后野生型小鼠凝血酶暴露下静脉凝血增加(p=0.0033),与瓣膜敲除FoxC2(FoxC2del)相当,重现FoxC2敲除动物表型。
- 多重伤联合FoxC2敲除导致50%动物出现自发性微血栓,单独多重伤或单独FoxC2缺陷均未观察到此表型(χ²检验,p=0.017)。
- 人静脉标本免疫荧光显示保护性瓣膜表型FOXC2和PROX1表达增加,危重症器官捐献者样本中表达降低。
证据类型、等级与局限
- 证据类型:动物实验及人标本观察性分析。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为已建立无需直接限制静脉血流或直接损伤血管内皮即可检测高凝状态的新型创伤后高凝模型,联合瓣膜特异性FOXC2敲除可产生自发性微血栓。
- 作者发现多重伤诱导促凝表型,重现FOXC2敲除中瓣膜高凝状态,并在危重症人标本中发现FOXC2和PROX1的振荡剪切应力诱导基因表达丢失证据,与DVT保护性瓣膜表型潜在丢失一致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Deep venous thrombosis (DVT) causes significant morbidity and mortality after trauma. Recently, we have shown that blood flow patterns at vein valves induce oscillatory stress genes, which maintain an anticoagulant endothelial phenotype that inhibits spontaneous clotting at vein valves and sinuses, is lost in the presence of DVT in human pathological samples, and is dependent on expression of the transcription factor FOXC2. We describe an assay, modifying our mouse multiple injury system, which shows evidence of clinically relevant microthrombosis and hypercoagulability applicable to the study of spontaneous DVT in trauma without requiring direct vascular injury or ligation. Finally, we investigated whether these model findings are relevant to a human model of critical illness by examining gene expression changes by quantitative polymerase chain reaction and immunofluorescence in veins collected from critically ill.
METHODS: C57/Bl6 mice were subjected to a modified mouse multiple injury model with liver crush injury, crush and pseudofracture of a single lower extremity, and 15% total blood volume hemorrhage. Serum was assayed for d-dimer at 2, 6, 24, and 48 hours after injury by enzyme-linked immunosorbent assay. For the thrombin clotting assay, veins of the leg were exposed, 100 μL of 1 mM rhodamine (6 g) was injected retro-orbitally, and 450 μg/mL thrombin was then applied to the surface of the vein with examination of real-time clot formation via in vivo immunofluorescence microscopy. Images were then examined for percentage area of clot coverage of visible mouse saphenous and common femoral vein. Vein valve specific knockout of FOXC2 was induced with tamoxifen treatment in PROX1 Ert2Cre FOXC2 fl/fl mice as previously described. Animals were then subjected to a modified mouse multiple injury model with liver crush injury, crush and pseudofracture of a single lower extremity, and 15% total blood volume hemorrhage. Twenty-four hours after injury, we examined the valve phenotype in naive versus multiple injury animals, with and without loss of the FOXC2 gene from the vein valve (FOXC2 del ) via the thrombin assay. Images were then examined for proximity of clot formation to the valve present at the junction of the mouse saphenous, tibial, and superficial femoral vein and presence of spontaneous microthrombi present in the veins before exposure to thrombin. Human vein samples were obtained from excess tissue preserved after harvest for elective cardiac surgery and from organ donors after organ procurement. Sections were submitted for paraffin embedding and then assayed by immunofluorescence for PROX1, FOXC2, thrombomodulin, endothelial protein C receptor, and von Willebrand's factor. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee, and all human studies reviewed and approved by the institutional review board.
RESULTS: After mouse multiple injuries, enzyme-linked immunosorbent assay for d-dimer showed evidence of products of fibrin breakdown consistent with formation of clot related to injury, fibrinolysis, and/or microthrombosis. The thrombin clotting assay demonstrated higher percentage area of vein covered with clot when exposed to thrombin in the multiple injury animals compared with uninjured (45% vs. 27% p = 0.0002) consistent with a phenotype of hypercoagulable state after trauma in our model system. Unmanipulated FoxC2 knockout mice manifest increased clotting at the vein valve as compared with unmanipulated wild type animals. After multiple injuries, wild type mice manifest increase clotting at the vein after thrombin exposure ( p = 0.0033), and equivalent to that of valvular knockout of FoxC2 (FoxC2del), recapitulating the phenotype seen in FoxC2 knockout animals. The combination of multiple injuries and FoxC2 knockout resulted in spontaneous microthrombi in 50% of the animals, a phenotype not observed with either multiple injuries or FoxC2 deficiency alone (χ 2 , p = 0.017). Finally, human vein samples demonstrated the protective vein valve phenotype of increased FOXC2 and PROX1 and showed decreased expression in the critically ill organ donor population by immunofluorescence imaging in organ donor samples.
CONCLUSION: We have established a novel model of posttrauma hypercoagulation that does not require direct restriction of venous flow or direct injury to the vessel endothelium to assay for hypercoagulability and can generate spontaneous microthrombosis when combined with valve-specific FOXC2 knockout. We find that multiple injuries induce a procoagulant phenotype that recapitulates the valvular hypercoagulability seen in FOXC2 knockout and, in critically ill human specimens, find evidence for loss of oscillatory shear stress-induced gene expression of FOXC2 and PROX1 in the valvular endothelium consistent with potential loss of DVT-protective valvular phenotype.
参考来源
- Hoofnagle MH, Hess A, Nalugo M, et al. Defects in vein valve PROX1/FOXC2 antithrombotic pathway in endothelial cells drive the hypercoagulable state induced by trauma and critical illness. J Trauma Acute Care Surg. 2023. PMID: 37072887. doi:10.1097/TA.0000000000003945
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。